In short
This article discusses recent clinical trials investigating the use of Phleum Pratense (225), commonly known as Timothy grass pollen extract, in treating moderate to severe allergic rhinitis and rhinoconjunctivitis. These studies aim to evaluate the efficacy and safety of different immunotherapy approaches using this allergen extract to improve symptoms and quality of life for grass pollen allergy sufferers.
At a glance
- Study Types
- Phase II-III clinical trials
- Main Objective
- To assess efficacy and safety of Phleum Pratense (225) immunotherapy for grass pollen allergy
- Treatment Methods
- Sublingual immunotherapy (SLIT), Intralymphatic immunotherapy (ILIT)
- Target Population
- Adults 18-65 with moderate to severe grass pollen allergic rhinitis/rhinoconjunctivitis
- Primary Outcome
- Combined Symptom and Medication Score (CSMS) during peak pollen season
- Secondary Outcomes
- Quality of life, individual symptom scores, immunological markers
- Innovative Approaches
- Combination of ILIT with vitamin D supplementation
- Safety Assessments
- Monitoring of adverse events, lung function tests (for asthmatic patients)
What is Phleum Pratense (225)?
Phleum pratense (225), also known as Timothy Grass, is a type of grass pollen that is commonly used in allergy treatments. It is an allergen extract derived from timothy grass, which is a common cause of hay fever and other allergic reactions in many people. This substance is used in various forms of immunotherapy to help reduce allergic reactions to grass pollen.
Medical Conditions Treated
Phleum pratense (225) is primarily used to treat moderate-to-severe allergic rhinitis and rhinoconjunctivitis caused by grass pollen allergy. These conditions involve symptoms such as:
- Sneezing
- Runny or stuffy nose
- Itchy or watery eyes
- Itchy throat or ears
The treatment is typically recommended for patients who have experienced these symptoms for at least two years and whose symptoms are not adequately controlled by conventional allergy medications.
Forms of Treatment
Phleum pratense (225) is administered in several forms of immunotherapy:
- Sublingual Immunotherapy (SLIT): This involves taking a tablet or drops containing the allergen extract under the tongue daily. An example of this is GRAZAX, a sublingual tablet containing 75,000 SQ-T units of Phleum pratense extract.
- Subcutaneous Immunotherapy (SCIT): This involves receiving injections of the allergen extract under the skin, typically administered by a healthcare professional. Alutard SQ Timotej is an example of a product used for SCIT, containing 10,000 SQ-E/ml of Phleum pratense extract.
- Intralymphatic Immunotherapy (ILIT): This is a newer form of treatment being studied, where the allergen extract is injected directly into lymph nodes.
Effectiveness
Clinical trials have shown that immunotherapy with Phleum pratense (225) can be effective in reducing allergy symptoms and the need for medication during grass pollen season. The effectiveness is typically measured using the Combined Symptom and Medication Score (CSMS), which takes into account both the severity of allergy symptoms and the amount of rescue medication needed.
Patients often experience improvement in their quality of life, as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). The treatment can also increase the number of "well days" during pollen season, defined as days with minimal symptoms and no need for rescue medication.
Side Effects and Safety
While immunotherapy with Phleum pratense (225) is generally considered safe, it can cause side effects. Common side effects may include:
- Itching or swelling in the mouth (for sublingual therapy)
- Local reactions at the injection site (for subcutaneous therapy)
- Mild allergic reactions
In rare cases, more severe allergic reactions can occur. Therefore, the treatment is typically started under medical supervision, and patients are monitored for adverse reactions.
Ongoing Research
Current research is exploring new ways to improve the effectiveness and safety of immunotherapy with Phleum pratense (225). Some areas of ongoing study include:
- Combining immunotherapy with vitamin D supplementation to potentially enhance its effects
- Comparing the effectiveness of different routes of administration (sublingual vs. subcutaneous vs. intralymphatic)
- Investigating optimal dosing regimens to maximize effectiveness while minimizing side effects
These studies aim to provide more personalized and effective treatment options for patients with grass pollen allergies in the future.